经皮冠状动脉介入治疗后P2Y12抑制剂与阿司匹林单药治疗的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入5项随机试验共16117例PCI后完成推荐DAPT疗程(中位12个月)的患者,比较P2Y12抑制剂单药与阿司匹林单药。中位随访1351天,P2Y12抑制剂单药组MACCE风险低于阿司匹林单药组(HR 0.77,95%CI 0.67-0.89,P<0.001),NNT为45.5;大出血无显著差异(HR 1.26,95%CI 0.78-2.04,P=0.35)。NACCE、心肌梗死和卒中在P2Y12抑制剂组更低。结论认为PCI后停用DAPT约5.5年随访时,替格瑞洛或氯吡格雷单药较阿司匹林降低MACCE且不增加大出血。
要点
- PCI后完成推荐DAPT(中位12个月)的患者,P2Y12抑制剂单药较阿司匹林单药降低MACCE(HR 0.77,95%CI 0.67-0.89,P<0.001),NNT=45.5。
- 大出血无显著差异:P2Y12抑制剂单药 vs 阿司匹林单药 HR 1.26(95%CI 0.78-2.04,P=0.35)。
- NACCE、心肌梗死和卒中在P2Y12抑制剂单药组均低于阿司匹林单药组。
- 中位随访1351天(约5.5年),获益在多项敏感性和亚组分析中一致。
- 结论支持PCI后停用DAPT时,替格瑞洛或氯吡格雷单药较阿司匹林单药降低MACCE且不增加大出血。
适用人群与场景
- 接受PCI并完成推荐DAPT疗程(中位12个月)后停用DAPT的冠状动脉疾病患者,来自5项随机试验共16117例。
研究设计与关键结果
- 研究类型:个体患者数据荟萃分析,纳入5项随机试验共16117例PCI后完成推荐DAPT(中位12个月)的患者。
- 主要终点MACCE:P2Y12抑制剂单药组 vs 阿司匹林单药组 HR 0.77(95%CI 0.67-0.89,P<0.001),NNT=45.5(95%CI 31.4-93.6)。
- 共同主要终点大出血:P2Y12抑制剂单药组 vs 阿司匹林单药组 HR 1.26(95%CI 0.78-2.04,P=0.35),无显著差异。
- 关键次要终点:NACCE、心肌梗死和卒中在P2Y12抑制剂单药组低于阿司匹林单药组。
- 中位随访1351天(四分位间距373-1791天),结论在多项敏感性和亚组分析中一致。
证据类型、等级与局限
- 证据类型:个体患者数据荟萃分析(5项随机对照试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,PCI后停用DAPT的患者,替格瑞洛或氯吡格雷单药较阿司匹林单药降低MACCE(HR 0.77),且不增加大出血风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the long term comparative effectiveness of P2Y12 inhibitor monotherapy compared with aspirin monotherapy in patients after percutaneous coronary intervention (PCI) and discontinuation of dual antiplatelet therapy (DAPT).
DESIGN: Individual participant data (IPD) meta-analysis of randomised clinical trials.
DATA SOURCES: PubMed/Medline, Scopus, Web of Science, and Ovid/Embase.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised trials investigating monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention of ischaemic events in patients with coronary artery disease who underwent PCI.
DATA EXTRACTION AND SYNTHESIS: Anonymised IPD were extracted and transferred to the coordinating centre by dedicated electronic spreadsheets. Data were primarily combined by mixed effects models (one stage analysis) and complemented with multivariable mixed effects models and two stage analyses based on random effects models. The primary and co-primary outcomes were a composite of major adverse cardiac and cerebrovascular events (MACCE) and major bleeding, respectively. The secondary outcomes included a net composite of adverse cardiac and cerebrovascular events (NACCE), derived from the combination of the primary and co-primary outcomes, and individual ischaemic and bleeding events.
RESULTS: A total of 16 117 patients assigned to P2Y12 inhibitor or aspirin monotherapy after PCI and completion of the recommended DAPT regimen (median duration of 12 months) in five randomised trials were included. At a median follow-up of 1351 days (interquartile range 373-1791 days), P2Y12 inhibitor monotherapy was associated with a lower risk of MACCE compared with aspirin monotherapy (one stage analysis: hazard ratio 0.77 (95% confidence interval (CI) 0.67 to 0.89), P<0.001; multivariable one stage analysis: adjusted hazard ratio 0.77 (0.67 to 0.89), P<0.001; two stage analysis: hazard ratio 0.77 (0.67 to 0.89), P<0.001), yielding a number needed to treat to benefit of 45.5 (95% CI 31.4 to 93.6). No significant difference in major bleeding (one stage analysis: hazard ratio 1.26 (0.78 to 2.04), P=0.35; multivariable one stage analysis: 1.12 (0.74 to 1.70), P=0.60; two stage analysis: 1.15 (0.69 to 1.92), P=0.59) was observed. NACCE, myocardial infarction, and stroke were lower in patients assigned to a P2Y12 inhibitor compared with those assigned to aspirin. These findings were confirmed across multiple sensitivity and subgroup analyses.
CONCLUSIONS: In patients who had undergone PCI and discontinued DAPT, at a follow-up of about 5.5 years, P2Y12 inhibitor monotherapy with ticagrelor or clopidogrel was associated with lower MACCE, owing to reduced rates of myocardial infarction and stroke compared with aspirin monotherapy, without a concurrent increased risk of major bleeding.
REVIEW REGISTRATION: PROSPERO CRD42024517983.
参考来源
- Giacoppo D, Gragnano F, Watanabe H, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ. 2025. PMID: 40467090. doi:10.1136/bmj-2024-082561
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。